The Report Scope:
The study scope includes clinical therapies using gene editing, gene therapy, genetically modified cell therapy (chimeric antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms. Delivery technologies covered include AAV, adenovirus, lentivirus, retrovirus, other viral and nonviral. Disease areas covered include cardiology, oncology, ophthalmology, hematology, musculoskeletal, neurology, rare diseases and others. Therapies that are already commercialized or are forecast to be commercialized with the next five years are included.
We analyze key genetic modification therapy technologies and products to determine present and future market status and forecasted growth from 2018 through 2023. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.
This Research examines the genetic modification therapies industry by market segment, including the following segments: gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production. The geographic market for genetic modification therapy products by platform technology is analyzed. Regions include North America, Europe, Asia-Pacific and the rest of the world.
The role of key strategic alliances and acquisitions from Jan. 2016 through June 2018 is discussed.
The challenges involved with pricing for genetic modification therapies that can offer one-time cures for diseases is discussed. Emerging markets for clinical gene editing are analyzed. More than 145 companies in the genetic modification therapies industry are profiled.
The Report Includes:
- 30 data tables and 56 additional tables
- An overview of the global market for genetic modification therapies
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on the genetic variation analysis and genetic modification technologies
- Evaluation of key growth driving forces, acquisitions and strategic alliances related to the market
- Detailed description of the criteria for selecting gene modification therapy applications
- Review of patents for gene editing, gene therapy, RNA therapy and gene modification therapies
- Profiles of the key companies in the market, including 4d Molecular Therapeutics LLC, Abeona Therapeutics LLC, Acer Therapeutics Inc., Allergan Plc and American Gene Technologies International Inc
Membership Price:
Contact us for membership pricing.
Table of Contents
Samples
LOADING...
Executive Summary
Genetic modification therapies are changing the landscape of medicine due to their unprecedented ability to offer a one-time cure for severe, debilitating diseases that were previously untreatable. Genetic modification therapies are advanced therapies that use genetic material (i.e., DNA or RNA) to treat diseases.
The four main genetic modification therapy platform technologies covered in this report include gene therapies, genetically modified cell therapies, RNA therapies, and gene editing.
In Dec. 2017, Luxturna became the first gene therapy approved for treating a genetic disorder. Luxturna is indicated for treating a severe inherited retinal disorder caused by a mutation in a single gene. Luxturna meets a clear and pressing medical need of restoring functional vision to a patient.
Besides Luxturna, several genetic modification therapies have been approved, including Kymarih and Yescarta (genetically modified cell therapy), Spinraza (RNA therapy) and others, setting the stage for strong market growth in the next five years.
Reasons for Doing the Study
Genetic modification therapies, particularly gene therapy and RNA therapy, have existed for many years, with little clinical success. However, recent improvements in these therapies, including better delivery systems, more efficient and durable gene expression constructs, precise DNA editing tools, have brought this industry to the forefront, and it is now poised for explosive growth in the coming years.
Because of the potentially curative nature of these medicines there is enormous potential in many applications, ranging from cancer to neurology to rare diseases. Genetic modification therapies represent the next wave of medicines with enormous potential for treating and curing debilitating and serious diseases. Because of its wide scope, genetic modification therapy will play an important role in the future global medical economy.
Continuing advances in key technologies such as DNA editing, viral design and production, and gene expression, as well as a pressing medical need in many serious and debilitating disorders, are driving the growth of the market for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for genetic modification therapy products.
Based on these market and technology dynamics, it is especially timely to comprehensively examine the current and future markets for genetic modification therapies.
Companies Mentioned
- 4D Molecular Therapeutics
- Abclon
- Abeona Therapeutics Llc
- Acer Therapeutics Inc.
- Adaptimmune Therapeutics
- Advantagene Inc.
- Adverum Biotechnologies
- Aevi Genomic Medicine Inc.
- Agilis Biotherapeutics
- Aldevron
- Allergan Plc
- Allogene Therapeutics Inc.
- American Gene Technologies International Inc.
- Amgen Inc.
- Anges Inc.
- Apeiron Biologics Ag
- Applied Genetic Technologies Corp.
- Arbor Biotechnologies Inc.
- Arcturus Therapeutics Inc.
- Asklepios Biopharmaceutical Inc.
- Astellas Pharma Inc.
- Audentes Therapeutics Inc.
- Avacta Group Plc
- Avrobio Inc.
- B-Mogen Biotechnologies Inc.
- Beam Therapeutics Inc.
- Bellicum Pharmaceuticals Inc.
- Binex Co. Ltd.
- Biocurepharm Corp.
- Biogen Inc.
- Biomarin Pharmaceutical Inc.
- Bluebird Bio
- Brammer Bio
- Caribou Biosciences
- Casebia Therapeutics
- Catherics Pty Ltd.
- Celgene Corp.
- Cell Medica Ltd.
- Cellectis Sa
- Cellular Biomedicine Group
- Celyad
- Cognate Bioservices
- Combigene Ab
- Crispr Therapeutics Ag
- CSL Behring Llc
- Curocell Co. Ltd.
- Editas Medicine Inc.
- Encoded Genomics Inc.
- Errant Gene Therapeutics Llc
- Esteve
- Etagen Pharma
- Eutilex Co. Ltd.
- Fate Therapeutics Inc.
- Ferring Pharmaceuticals Sa
- Fibrocell Science
- FKD Therapies Oy
- Fortress Biotech Inc.
- Freeline Therapeutics
- GE Healthcare
- Gene Biotherapeutics Inc.
- Genenta Science Srl
- Generation Bio
- Genethon Sa
- Gensight Biologics Sa
- Gilead Sciences Inc.
- Glaxosmithkline Plc
- Global Biotherapeutics Usa Inc.
- Green Cross Cell Corp.
- Hemera Biosciences Inc.
- Hitachi Chemical Advanced Therapeutics Llc
- Homology Medicines Inc.
- Horama Sa
- Immunochina Pharmaceuticals
- Immunocore Ltd.
- Indee Labs Inc.
- Intellia Therapeutics Inc.
- Intrexon Corp.
- Jivana Biotechnology
- Johnson & Johnson
- Juventas Therapeutics Inc.
- Kolon Life Sciences Inc.
- Krystal Biotech
- Kubota Pharmaceutical Holdings Co. Ltd.
- Limelight Bio Inc.
- Logicbio Therapeutics Inc.
- Lonza Group Ltd.
- Lysogene Sa
- Marcala Biotech Inc.
- Maxcyte Inc.
- Medigene Ag
- Meira Gtx
- Merck & Co.
- Merck Kgaa
- Mesoblast Ltd.
- Millipore Sigma
- Milo Biotechnology Llc
- Molmed Spa
- Morphogenesis Inc.
- Myonexus Therapeutics Inc.
- Nantkwest Inc.
- Newlink Genetics Corp.
- Neximmune Inc.
- Nightstar Therapeutics Plc
- Novartis Pharma Ag
- Novasep Llc
- Ocunexus Therapeutics Inc.
- Orchard Therapeutics
- Oxford Biomedica Plc
- Pepromene Bio Inc.
- Periphagen Inc.
- Pfizer Inc.
- Poseida Therapeutics Inc.
- Precision Bioscience
- Regenxbio Inc.
- Renova Therapeutics
- Rocket Pharma Ltd.
- RXI Pharmaceuticals Corp.
- Sangamo Therapeutics Inc.
- Sanofi Sa
- Sarepta Therapeutics Inc.
- Selecta Biosciences Inc.
- Senti Biosciences
- Shire Plc
- Sibiono Genetech Co. Ltd.
- Sillagen Biotherapeutics
- Solid Biosciences Llc
- Spark Therapeutics Inc.
- Synpromics Ltd.
- Takara Bio
- Theragene Pharmaceuticals Inc.
- Thermo Fisher Scientific
- Tocagen
- Toolgen
- Transgene Sa
- Translate Bio
- Tx Cell
- Ultragenyx Pharmaceutical Inc.
- Uniqure Nv
- Unum Therapeutics Inc.
- Vascular Biogenics Ltd.
- Viracta Therapeutics
- Viromed Co. Ltd.
- Vivet Therapeutics
- Voyager Therapeutics Inc.
- Wuxi Apptech
- Ziopharm Oncology